Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the first-line standard of care for advanced non-small cell lung cancer (NSCLC) patients with EGFR-sensitive mutations (1, 2). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.